Published in Nat Rev Endocrinol on May 05, 2015
DHEA in women with hypoandrogenism--debate remains open. Nat Rev Endocrinol (2015) 0.83
More on the conversion of DHEA to testosterone. Nat Rev Endocrinol (2015) 0.75
Potential therapeutic applications of human anti-Müllerian hormone (AMH) analogues in reproductive medicine. J Assist Reprod Genet (2017) 0.75
The BMP4-Smad Signaling Pathway Regulates Hyperandrogenism Development in a Female Mouse Model. J Biol Chem (2017) 0.75
The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res (1994) 3.52
Role of endocytosis in cellular uptake of sex steroids. Cell (2005) 3.49
Sex-hormone-binding globulin and the free androgen index are related to cardiovascular risk factors in multiethnic premenopausal and perimenopausal women enrolled in the Study of Women Across the Nation (SWAN). Circulation (2005) 3.01
Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med (2000) 3.00
Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med (2013) 2.37
Treatment with tumor necrosis factor inhibitors and intravenous immunoglobulin improves live birth rates in women with recurrent spontaneous abortion. Am J Reprod Immunol (2008) 2.23
Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med (1999) 2.13
Sulfonation and molecular action. Endocr Rev (2002) 2.13
Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J Clin Oncol (2009) 2.03
Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reprod Biol Endocrinol (2011) 2.02
Androgens stimulate early stages of follicular growth in the primate ovary. J Clin Invest (1998) 2.00
A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab (1991) 1.96
Reduced transcriptional regulatory competence of the androgen receptor in X-linked spinal and bulbar muscular atrophy. Nat Genet (1993) 1.93
Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: possible pathogenetic relevance for the (CAG)n-expanded neuronopathies. Hum Mol Genet (1995) 1.91
Long polyglutamine tracts in the androgen receptor are associated with reduced trans-activation, impaired sperm production, and male infertility. J Clin Endocrinol Metab (1997) 1.88
Which follicles make the most anti-Mullerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection. Mol Hum Reprod (2013) 1.80
Structural and functional consequences of glutamine tract variation in the androgen receptor. Hum Mol Genet (2004) 1.74
Clinical evidence for a detrimental effect on uterine receptivity of high serum oestradiol concentrations in high and normal responder patients. Hum Reprod (1995) 1.74
Androgen and follicle-stimulating hormone interactions in primate ovarian follicle development. J Clin Endocrinol Metab (1999) 1.74
Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity. Lupus (2004) 1.73
Steroid sulfatase: molecular biology, regulation, and inhibition. Endocr Rev (2004) 1.69
CGG repeat in the FMR1 gene: size matters. Clin Genet (2011) 1.68
Treatment with adalimumab (Humira) and intravenous immunoglobulin improves pregnancy rates in women undergoing IVF. Am J Reprod Immunol (2008) 1.68
Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology (1990) 1.64
Association of FMR1 genotypes with in vitro fertilization (IVF) outcomes based on ethnicity/race. PLoS One (2011) 1.60
Premature ovarian failure in patients with autoimmune Addison's disease: clinical, genetic, and immunological evaluation. J Clin Endocrinol Metab (2011) 1.60
Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev (2003) 1.60
The human androgen receptor: domain structure, genomic organization and regulation of expression. J Steroid Biochem (1989) 1.58
Granulosa cell-specific androgen receptors are critical regulators of ovarian development and function. Mol Endocrinol (2010) 1.57
DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology. Front Neuroendocrinol (2001) 1.57
The effect of transdermal testosterone gel pretreatment on controlled ovarian stimulation and IVF outcome in low responders. Fertil Steril (2011) 1.57
Aromatase inhibitors in ovarian stimulation for IVF/ICSI: a pilot study. Reprod Biomed Online (2006) 1.56
Testosterone concentrations, using different assays, in different types of ovarian insufficiency: a systematic review and meta-analysis. Hum Reprod Update (2012) 1.48
Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone. J Biol Chem (2007) 1.47
The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol (Oxf) (1998) 1.45
Review: aromatase inhibitors for ovulation induction. J Clin Endocrinol Metab (2005) 1.45
Premature ovarian failure in androgen receptor-deficient mice. Proc Natl Acad Sci U S A (2005) 1.44
Finasteride in the treatment of hirsutism: new therapeutic perspectives. Fertil Steril (1996) 1.43
Androgen receptor gene expression in the primate ovary: cellular localization, regulation, and functional correlations. J Clin Endocrinol Metab (1998) 1.42
FMR1 and the continuum of primary ovarian insufficiency. Semin Reprod Med (2011) 1.42
Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length. Hum Mol Genet (2000) 1.41
Subfertility and defective folliculogenesis in female mice lacking androgen receptor. Proc Natl Acad Sci U S A (2004) 1.39
Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene (2000) 1.38
EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells. Evidence of a BRCA1 and p300 exchange. J Biol Chem (2007) 1.36
Adrenal and gonadal androgen secretion in normal females. Clin Endocrinol Metab (1986) 1.35
Common genetic variation in the sex steroid hormone-binding globulin (SHBG) gene and circulating shbg levels among postmenopausal women: the Multiethnic Cohort. J Clin Endocrinol Metab (2005) 1.32
Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. Ann Oncol (2002) 1.30
Eight common genetic variants associated with serum DHEAS levels suggest a key role in ageing mechanisms. PLoS Genet (2011) 1.30
The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: a pilot study. Fertil Steril (2005) 1.27
Interrelation between plasma sex hormone-binding globulin and plasma insulin in healthy adult women: the telecom study. J Clin Endocrinol Metab (1993) 1.27
FMR1 genotype with autoimmunity-associated polycystic ovary-like phenotype and decreased pregnancy chance. PLoS One (2010) 1.26
Pharmacogenetics of human cytosolic sulfotransferases. Oncogene (2006) 1.26
Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression. Oncogene (2005) 1.25
Ovarian volume and antral follicle count for the prediction of low and hyper responders with in vitro fertilization. Reprod Biol Endocrinol (2007) 1.23
Ovarian and adrenal contribution to peripheral androgens during the menstrual cycle. J Clin Endocrinol Metab (1974) 1.21
The role of androgens in follicle maturation and ovulation induction: friend or foe of infertility treatment? Reprod Biol Endocrinol (2011) 1.20
Variants in the 5alpha-reductase type 1 and type 2 genes are associated with polycystic ovary syndrome and the severity of hirsutism in affected women. J Clin Endocrinol Metab (2006) 1.19
Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) (2005) 1.17
Dehydroepiandrosterone (DHEA)--a precursor steroid or an active hormone in human physiology. J Sex Med (2011) 1.16
Starting and resulting testosterone levels after androgen supplementation determine at all ages in vitro fertilization (IVF) pregnancy rates in women with diminished ovarian reserve (DOR). J Assist Reprod Genet (2012) 1.16
Hypoandrogenism in association with diminished functional ovarian reserve. Hum Reprod (2013) 1.14
Efficacy of dehydroepiandrosterone to improve ovarian response in women with diminished ovarian reserve: a meta-analysis. Reprod Biol Endocrinol (2013) 1.12
Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II. Pharmacogenetics (2000) 1.11
Female mice haploinsufficient for an inactivated androgen receptor (AR) exhibit age-dependent defects that resemble the AR null phenotype of dysfunctional late follicle development, ovulation, and fertility. Endocrinology (2007) 1.11
Beyond adrenal and ovarian androgen generation: Increased peripheral 5 alpha-reductase activity in women with polycystic ovary syndrome. J Clin Endocrinol Metab (2003) 1.09
Advanced reproductive age and fertility. J Obstet Gynaecol Can (2011) 1.08
Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial. J Clin Endocrinol Metab (2007) 1.08
Autoimmunity and antigenic targets in ovarian pathology. Hum Reprod Update (2004) 1.07
Poor responders and androgen adjuvant treatment: "Still haven't found what I'm looking for …". Reprod Biomed Online (2014) 1.07
The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome. Hum Reprod (2009) 1.07
Dehydroepiandrosterone and dehydroepiandrosterone sulfate production in the human adrenal during development and aging. Steroids (1999) 1.06
Differences in ovarian aging patterns between races are associated with ovarian genotypes and sub-genotypes of the FMR1 gene. Reprod Biol Endocrinol (2012) 1.06
No association between a single nucleotide polymorphism in CYP19 and breast cancer risk. Cancer Epidemiol Biomarkers Prev (2002) 1.06
Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations. J Clin Endocrinol Metab (2009) 1.06
Effects of a two-week physiological dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly women and men. J Clin Endocrinol Metab (1997) 1.05
Sex hormone-binding protein, hyperinsulinemia, insulin resistance and noninsulin-dependent diabetes. Horm Res (1996) 1.04
Effect of dietery weight loss on sex steroid binding sex steroids, and gonadotropins in obese postmenopausal women. J Lab Clin Med (1979) 1.03
Human sex hormone-binding globulin promoter activity is influenced by a (TAAAA)n repeat element within an Alu sequence. J Biol Chem (2001) 1.03
The molecular genetics of steroid 5 alpha-reductases. Recent Prog Horm Res (1994) 1.02
Dehydroepiandrosterone metabolism. J Endocrinol (1996) 1.02
Twenty-four-hour mean plasma testosterone concentration declines with age in normal premenopausal women. J Clin Endocrinol Metab (1995) 1.02
Do etiologies of premature ovarian aging (POA) mimic those of premature ovarian failure (POF)? Hum Reprod (2009) 1.02
Aromatase gene (CYP 19) polymorphisms and endogenous androgen concentrations in a multiracial/multiethnic, multisite study of women at midlife. Am J Med (2006) 1.01
Androgen and estrogen signaling at the cell membrane via G-proteins and cyclic adenosine monophosphate. Steroids (1999) 1.00
Functional AR signaling is evident in an in vitro mouse follicle culture bioassay that encompasses most stages of folliculogenesis. Biol Reprod (2008) 1.00
5alpha-reductase activity in women with polycystic ovary syndrome. J Clin Endocrinol Metab (1999) 1.00
Heritability of variation of plasma cortisol levels. Metabolism (1988) 1.00
Standardization of hormonal assays for the 21st century. J Clin Endocrinol Metab (2010) 0.99
Developmental regulation of androgen receptor in rat ovary. J Endocrinol (1995) 0.99
Endocrine autoimmune diseases and female infertility. Nat Rev Endocrinol (2013) 0.98
Autoantibodies to steroidogenic enzymes in autoimmune polyglandular syndrome, Addison's disease, and premature ovarian failure. J Clin Endocrinol Metab (1996) 0.98
Aromatase expression is increased in BRCA1 mutation carriers. BMC Cancer (2009) 0.97
Dehydroepiandrosterone: is there a role for replacement? Mayo Clin Proc (2003) 0.97
Should androgen supplementation be used for poor ovarian response in IVF? Hum Reprod (2012) 0.96
Testosterone, not 5α-dihydrotestosterone, stimulates LRH-1 leading to FSH-independent expression of Cyp19 and P450scc in granulosa cells. Mol Endocrinol (2011) 0.96
Dehydroepiandrosterone and its metabolites: differential effects on androgen receptor trafficking and transcriptional activity. J Steroid Biochem Mol Biol (2006) 0.95
BRCA1 negatively regulates the cancer-associated aromatase promoters I.3 and II in breast adipose fibroblasts and malignant epithelial cells. J Clin Endocrinol Metab (2006) 0.95
A genetic component to the variation of dehydroepiandrosterone sulfate. Metabolism (1985) 0.95
Association of the (TAAAA)n repeat polymorphism in the sex hormone-binding globulin (SHBG) gene with polycystic ovary syndrome and relation to SHBG serum levels. J Clin Endocrinol Metab (2003) 0.95
More on the conversion of DHEA to testosterone. Nat Rev Endocrinol (2015) 0.75